BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ocrelizumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ocrelizumab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04466150-6975@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ocrelizumab: Phase 4 readout est. (NCT04466150)
DESCRIPTION:Ocrelizumab\, phase 4\, Multiple Sclerosis.\nStudy: Impact of O
 crelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset\n
 Estimated primary completion: December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ocrelizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04466150
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05296161-6975@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ocrelizumab: Phase 4 readout est. (NCT05296161)
DESCRIPTION:Ocrelizumab\, phase 4\, Multiple Sclerosis.\nStudy: B Cell Tail
 ored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multip
 le Sclerosis\nEstimated primary completion: February 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ocrelizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05296161
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06495593-6975@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ocrelizumab: Phase 4 readout est. (NCT06495593)
DESCRIPTION:Ocrelizumab\, phase 4\, Multiple Sclerosis.\nStudy: Effects of 
 Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
 \nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ocrelizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06495593
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269004-6975@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ocrelizumab: Phase 3 readout est. (NCT05269004)
DESCRIPTION:Ocrelizumab\, phase 3\, Multiple Sclerosis.\nStudy: A Rollover 
 Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Pati
 ents With Multiple Sclerosis\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ocrelizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05269004
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483450-6975@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ocrelizumab: Phase 4 readout est. (NCT07483450)
DESCRIPTION:Ocrelizumab\, phase 4\, Multiple Sclerosis.\nStudy: A Study to 
 Evaluate the Efficacy\, Safety\, Pharmacokinetics\, and Pharmacodynamics o
 f Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primar
 y Progressive Multiple Sclerosis\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ocrelizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07483
 450
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05999604-6975@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Ocrelizumab: Phase 3 readout est. (NCT05999604)
DESCRIPTION:Ocrelizumab\, phase 3\, Multiple Sclerosis.\nStudy: Impact of A
 nnual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS\
 ,After 2 Years of Initial Treatment\, on Freedom From Radiological Disease
  Activity at Two Years: a Multicenter Randomized Controlled Non-inferiorit
 y Trial\nEstimated primary completion: May 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ocrelizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05999604
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181811-6975@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Ocrelizumab: Phase na readout est. (NCT07181811)
DESCRIPTION:Ocrelizumab\, phase na\, Multiple Sclerosis.\nStudy: Assessing 
 the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition 
 in Veterans With Multiple Sclerosis\nEstimated primary completion: 1 June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ocrelizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0718181
 1
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03971487-6975@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ocrelizumab: Phase 1/2 readout est. (NCT03971487)
DESCRIPTION:Ocrelizumab\, phase 1/2.\nStudy: Ocrelizumab for Psychosis by A
 utoimmunity\nEstimated primary completion: 30 June 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/ocrelizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03971487
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609719-6975@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Ocrelizumab: Phase 4 readout est. (NCT07609719)
DESCRIPTION:Ocrelizumab\, phase 4\, Multiple Sclerosis.\nStudy: A Study of 
 Ocrelizumab Administered Subcutaneously in Participants With Multiple Scle
 rosis Who Switch From an Approved Anti-CD20 Therapy\nEstimated primary com
 pletion: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ocrelizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07609719
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503340-6975@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Ocrelizumab: Phase 2 readout est. (NCT07503340)
DESCRIPTION:Ocrelizumab\, phase 2\, Multiple Sclerosis.\nStudy: A Study to 
 Evaluate Pharmacokinetics\, Safety\, Tolerability\, Immunogenicity and Pha
 rmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Childre
 n and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)\nEsti
 mated primary completion: 31 August 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ocrelizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07503340
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06675955-6975@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ocrelizumab: Phase 3 readout est. (NCT06675955)
DESCRIPTION:Ocrelizumab\, phase 3\, Multiple Sclerosis.\nStudy: An Extensio
 n Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function a
 nd Provide Continued Ocrelizumab Treatment\nEstimated primary completion: 
 31 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ocr
 elizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06675955
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05285891-6975@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20310825
DTEND;VALUE=DATE:20310826
SUMMARY:Ocrelizumab: Phase 4 readout est. (NCT05285891)
DESCRIPTION:Ocrelizumab\, phase 4\, Multiple Sclerosis.\nStudy: Ocrelizumab
  Discontinuation in Relapsing Multiple Sclerosis\nEstimated primary comple
 tion: 25 August 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ocrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05285891
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
